Dr. John H. Abeles
Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.
August 23, 2017 09:04 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) today announced that it has appointed John H. Abeles, M.D. as Chairman and CEO of its subsidiary, Cytocom,...
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017
May 31, 2017 09:14 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable,...
CORRECTING and REPLACING: Immune Therapeutics, Inc.
May 22, 2017 09:24 ET | Immune Therapeutics, Inc.
In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read "Immune Therapeutics Announces NAFDAC Approval...
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
May 22, 2017 08:42 ET | Immune Therapeutics, Inc.
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture...
Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya
April 25, 2017 11:37 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., April 25, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
April 17, 2017 11:44 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., April 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement
April 12, 2017 13:36 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., April 12, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio
March 30, 2017 09:45 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization
March 15, 2017 14:59 ET | Immune Therapeutics, Inc.
Highlights: Company Redeems Nearly All Outstanding Convertible DebenturesReplaces Nearly $650,000 of Long-Term Debt with Financing on Significantly Better Terms from a Strategic Long-Term...
IMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid Year
February 09, 2017 13:39 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and...